• For Acyclovir Lauriad®, the Company has engaged discussion with European regulatory agencies and obtained a registration slot. While standard drug development usually requests a second phase III trial prior to file for market authorization, BioAlliance Pharma has initiated promising discussion with European and US agencies to recognize Acyclovir Lauriad® clinical benefits and allow a much shorter process.
  • S1 2010 record turnover with €21.3 M versus €4.1 M for the same period in 2009. BioAlliance has again shown the capacity to reach on time important milestones, including its new European partnership with Therabel (March 2010), followed by the FDA approval of Loramyc®/ Oravig® (April 2010).


More details
 

Find an actor

Biomanufacturing A3P Congress31.05.2017

Conferences, Workshops, Exhibition, Plant Tour Bioproduction Efficiency

BioAlps Bridging the World : Worldwide Visibility Package 2017

A yearly international programme for our affiliated companies to increase their visibility
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

E-mail address
Powered by /boomerang